

OMB APPROVAL	
OMB Number:	3235-0362
Estimated average burden hours per response:	1.0

- Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
- Form 3 Holdings Reported.
- Form 4 Transactions Reported.

**ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>King Rachel K.</u>  (Last) (First) (Middle) C/O GLYCOMIMETICS, INC. 9708 MEDICAL CENTER DRIVE  (Street) ROCKVILLE MD 20850  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>GLYCOMIMETICS INC [ GLYC ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner  Officer (give title below) Other (specify below)
	3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 12/31/2022	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person  Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)
				Amount	(A) or (D)	Price			
Common Stock	02/15/2022		W	11,641	A	\$0.00	500,955 <sup>(1)(2)</sup>	D	
Common Stock	08/02/2022		W	7,500	A	\$0.00	7,500	I	By RBK LLC <sup>(3)</sup>
Common Stock							92,401	I	By trusts <sup>(4)</sup>
Common Stock							45,741	I	By spouse

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Ownership (Instr. 4)
					(A)	(D)	Date Exercisable	Expiration Date					

**Explanation of Responses:**

- Includes 48,125 shares underlying restricted stock units held as of the date of this report. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- This total also includes 37,000 shares previously held by The Rachel K. King 2016 GRAT that were transferred to the reporting person on February 25, 2021 and are now owned directly by the reporting person.
- The reporting person is co-manager of this entity. She disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein.
- These shares are held by family trusts, for which Ms. King serves as trustee, as follows: 1,741 shares are held by The Connor A. King 1988 Trust, 1,741 shares are held by The Langley C. King 1990 Trust, 8,796 shares are held by the 1995 Connor A. King Trust, 8,796 shares are held by the 1995 Langley C. King Trust, 23,301 shares are held by The Connor King 2013 GRAT, 23,301 shares are held by The Langley C. King 2013 GRAT and 24,725 shares are held by The Rachel K. King 2016 GRAT. The number of shares held by The Rachel K. King 2016 GRAT excludes the 37,000 shares transferred to the reporting person as described in footnote 2.

**Remarks:**

/s/ Brian F. Leaf, attorney-in-fact 02/06/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.